AMANDA KENT: Open Payments
NPI 1871254805 · JAMESTOWN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,877 in 195 payments from 14 companies in 2025. Trend: 2023 $1,469 · 2024 $2,337 · 2025 $2,877
Food & beverage: $2,877
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $532 |
| ABBVIE INC. | 25 | $364 |
| Axsome Therapeutics, Inc. | 11 | $312 |
| Teva Pharmaceuticals USA, Inc. | 27 | $298 |
| Lundbeck LLC | 29 | $285 |
| Otsuka America Pharmaceutical, Inc. | 18 | $282 |
| Neurocrine BioSciences, Inc. | 8 | $161 |
| Vanda Pharmaceuticals Inc. | 7 | $156 |
| Supernus Pharmaceuticals, Inc. | 12 | $147 |
| E.R. Squibb & Sons, L.L.C. | 13 | $144 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Auvelity, UZEDY, INGREZZA, Qelbree, COBENFY.
Industry payments across NY — which companies pay providers there.
